NEW YORK (GenomeWeb News) – The National Cancer Institute said today that it has struck two new partnerships, one with the National Heart, Lung, and Blood Institute and another with the Food and Drug Administration, to develop and support new proteomics research projects through its Office of Cancer Clinical Proteomics Research, or OCCPR.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

Harvard Medical School's George Church discusses editing human DNA, including germline DNA, in the New England Journal of Medicine.